Product Description
Phenelzine is a potent, non-selective monoamine oxidase inhibitor (MAOI) used in treating depression and as an anxiolytic in adults. It is a hydrazine derivative drug and is one of the few remaining non-selective monoamine oxidase inhibitors (along with tranylcypromine and isocarboxazid) still in regular clinical use. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK554508/)
Mechanisms of Action: MAO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Belgium | Canada | India | Ireland | Italy | New Zealand | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|